• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
ConclusionPatients with NVAF and  ≥ 6 comorbid conditions had significantly different risks for stroke/SE and MB when comparing DOACs to DOACs, and different healthcare expenses. This study's results may be useful for evaluating the risk–benefit ratio of DOAC use in patients with NVAF and multimorbidity.
Source: Advances in Therapy - December 17, 2022 Category: Drugs & Pharmacology Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France
ConclusionExtrahepatic manifestations of HCV infection substantially add to the overall economic burden of the disease in France. HCV cure after anti‐viral therapy is expected to significantly reduce the total costs of managing these manifestations in France.
Source: Alimentary Pharmacology and Therapeutics - October 18, 2017 Category: Drugs & Pharmacology Authors: P. Cacoub, M. Vautier, A. C. Desbois, D. Saadoun, Z. Younossi Tags: ORIGINAL ARTICLE Source Type: research

A Real-World Analysis of Patient Characteristics and Predictors of Hospitalization Among US Medicare Beneficiaries with Respiratory Syncytial Virus Infection
ConclusionHospitalized Medicare beneficiaries with RSV infections pose a significant healthcare burden as compared with non-hospitalized patients, mainly driven by higher comorbidity, higher likelihood of multiple inpatient admissions, and costly medical interventions.
Source: Advances in Therapy - February 4, 2020 Category: Drugs & Pharmacology Source Type: research

Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants
ConclusionThe significant adverse renal and cardiovascular outcomes observed, particularly in the DAPA-CKD-like cohort, represent a substantial burden resulting in increased mortality, HCRU and costs, demonstrating the need for additional treatment options.
Source: Advances in Therapy - January 20, 2021 Category: Drugs & Pharmacology Source Type: research

Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease
ConclusionsPatients with IBD experienced greater rates of DVT and PE compared to patients without IMD; this elevated risk was associated with a substantial economic burden.
Source: Advances in Therapy - December 7, 2021 Category: Drugs & Pharmacology Source Type: research

The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases
ConclusionAmong patients with IMDs, TEs are associated with substantial economic burden within 30-days and 1-year following the event.
Source: Advances in Therapy - December 14, 2021 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness of SAPIEN  3 Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in German Severe Aortic Stenosis Patients at Low Surgical Mortality Risk
ConclusionsTAVI with SAPIEN  3 appears to be a clinically meaningful, cost-effective treatment option over SAVR for patients with severe symptomatic aortic stenosis and low risk for surgical mortality in Germany.Clinical Trial Registration Numberwww.clinicaltrials.gov identifier: NCT02675114.
Source: Advances in Therapy - January 9, 2023 Category: Drugs & Pharmacology Source Type: research

Real-World Racial Variation in Treatment and Outcomes Among Patients with Peripheral Artery Disease
ConclusionsResults of this real-world study suggest that Black patients with PAD have higher disease severity at the time of diagnosis and are at increased risk of experiencing adverse outcomes following diagnosis.
Source: Advances in Therapy - March 6, 2023 Category: Drugs & Pharmacology Source Type: research